Sign In
Buy CGIX
$1.08
+0 (+0%)
At Close: May 27, 2022
Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering
05:54pm, Wednesday, 28'th Oct 2020
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology services, a
Wall Street Breakfast: What Moved Markets
02:01pm, Saturday, 29'th Aug 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Cancer Genetics Reports Second Quarter 2020 Financial Results
11:30am, Friday, 14'th Aug 2020
RUTHERFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announce
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates | MarketScreener
09:31pm, Wednesday, 24'th Jun 2020Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
09:30pm, Wednesday, 24'th Jun 2020
RUTHERFORD, N.J., June 24, 2020 -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today.
Cancer Genetics (NASDAQ:CGIX) Share Price Crosses Below Two Hundred Day Moving Average of $4.15
03:14am, Thursday, 18'th Jun 2020
Shares of Cancer Genetics Inc (NASDAQ:CGIX) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.15 and traded as low as $3.16. Cancer Ge
Cancer Genetics Q1 EPS $(0.14) Up From $(0.90) YoY, Sales $1.90M Down From $6.84M YoY
12:06pm, Monday, 01'st Jun 2020Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
12:00pm, Monday, 01'st Jun 2020
RUTHERFORD, N.J., June 01, 2020 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced.
IPO Update: Lantern Pharma Readies $25 Million IPO
05:51pm, Tuesday, 12'th May 2020
Lantern Pharma has filed to raise $25 million in a U.S. IPO. The firm seeks to advance previously-failed drugs through new trials. While I wish management well,
Those Who Purchased Cancer Genetics (NASDAQ:CGIX) Shares Five Years Ago Have A 99% Loss To Show For It
10:37am, Tuesday, 12'th May 2020
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. For example, we...
New York, April 30, 2020 -- Reportlinker.com announces the release of the report "Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End.
Mayo Clinic Buys Cancer Genetics Inc, Sells ClearPoint Neuro Inc
12:00am, Friday, 24'th Apr 2020The Lantern Pharma IPO Raises Some Questions
06:28pm, Thursday, 23'rd Apr 2020
We recently published a report on seven AI healthcare stocks noting that six were the result of recent IPOs. Of those, two are involved in drug discovery. We've written extensively about how machine l
Lantern Pharma Starts U.S. IPO Process
08:19pm, Friday, 17'th Apr 2020
Lantern Pharma has filed to raise $29 million in a U.S. IPO, although the final figure may differ. The firm is advancing a pipeline of drug treatment candidates
